Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein (Fred Hutchinson Cancer Research Center)

N/A

Report date: 2023/05/05 17:36:45

Base Information

Drug NameAnti-CD20 B9E9 scFv-Streptavidin Fusion Protein (Fred Hutchinson Cancer Research Center)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research CenterNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteFred Hutchinson Cancer Research Center
Inactive CompaniesN/A
Active IndicationsLymphoma, Mantle-CellLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin +[4] 
Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A